Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Prismx Global Ventures Ltd
BSE:501314
|
IN |
|
O
|
Optima Automobile Group Holdings Ltd
HKEX:8418
|
SG |
|
H
|
Heeros Oyj
OMXH:HEEROS
|
FI |
|
Scala Inc
TSE:4845
|
JP |
|
Himatsingka Seide Ltd
NSE:HIMATSEIDE
|
IN |
|
Oue Commercial Real Estate Investment Trust
SGX:TS0U
|
SG |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-19.91 (671% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -2.5 | $3.49 |
0%
|
| Industry Average | 14.3 | $-19.91 |
-671%
|
| Country Average | 19.6 | $-27.37 |
-884%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
341.6m USD | -2.5 | -2.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 20.3 | 88 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.4 | 24.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD | 15.5 | 20.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD | 22.2 | 28.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.4B EUR | 44.6 | 40.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.7 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
